LFB` Cevenfacta Receives Approval in Europe
LES ULIS, France--(BUSINESS WIRE)--LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups.
LES ULIS, France and LUCCA, Italy, Jan. 31, 2022 /PRNewswire/ -- Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.